| 查看: 433 | 回复: 0 | |||
chao1.zhang银虫 (小有名气)
|
[交流]
罗氏抗体-药物偶合新药上市，又一系列重磅开始？
|
|
Trastuzumab emtansine (INN; in the United States, ado-trastuzumab emtansine, trade name Kadcyla) is an antibody-drug conjugate consisting of the monoclonal antibody trastuzumab (Herceptin) linked to the cytotoxic agent mertansine (DM1).Trastuzumab alone kills cancer cells by binding to the HER2 receptor. The conjugate includes emtansine, which enters the cell and destroys the cell by binding to tubulin.Because monoclonal antibodies target HER2, and HER2 is only expressed in breast cancer cells, the conjugate delivers the toxin emtansine only to breast cancer cells.Meet the Bay Area's next blockbuster drug: T-DM1, a breast cancer-fighting treatment developed by Genentech Inc., leads the early Class of 2013 drugs seeking Food and Drug Administration approval. The FDA's decision date is Feb. 26. In the EMILIA clinical trial of women with advanced HER2 positive breast cancer who were already resistant to trastuzumab alone, it improved survival by 5.8 months compared to the combination of lapatinib and capecitabine. Based on that trial, the U.S. FDA approved marketing on February 22, 2013. |
回复此楼» 猜你喜欢
考研调剂：国家蛋白质科学中心（国家重点实验室）和安徽医科大学基础医学院联培
已经有4人回复
-
华南理工大学 基础医学学硕和临床医学学硕调剂
已经有11人回复
-
药理学论文润色/翻译怎么收费?
已经有188人回复
-
北京协和医学院杰青课题组招聘科研助理
已经有0人回复
-
北京协和医学院杰青课题组招聘科研助理
已经有0人回复
-
求助中国药典1995年版、二部
已经有0人回复
-
26申博-药化方向
已经有3人回复
-
北京协和医学院杰青课题组招聘科研助理
已经有0人回复
-
芳胺的还原胺化
已经有6人回复
-
求助https://www.pnas.org/doi/10.1073/pnas.2535777123 全文
已经有0人回复
